Pfizer: three launches inside eighteen months, limited competition on two
Three launches land inside eighteen months with limited competition on two of them. The market still prices this as a levered generics business.
Discussion · 7
I hold the other side of this. The channel data is what makes this hard to dismiss. Is there a cleaner way to express this than the equity?
This is the second-order point everyone skips. The installed base argument is stronger than the cycle argument here. What does the bear actually have to be right about?
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (914)
This lines up with what I saw in the filings. The mix argument is the part I had not considered properly. Has anything in the last print changed the entry you would take?
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (917)
Agree with the direction, less with the magnitude. The cohort split is the detail that everyone leaves out. What is the level where you would walk away?
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (912)